Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAM2056
- Development stage
- Phase 2
- Lead developer
- Camurus
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
CAM2056 is an investigational long-acting monthly subcutaneous depot formulation of semaglutide being developed by Camurus for the treatment of obesity and overweight. It utilizes Camurus' proprietary FluidCrystal® technology to enable extended-release and sustained delivery of the active ingredient. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that works to reduce body weight by decreasing appetite and energy intake. The drug is designed for monthly administration, potentially improving treatment adherence compared to existing weekly formulations. Clinical results from a Phase 1b trial demonstrated significant weight reduction with safety and tolerability profiles consistent with other semaglutide products.
- Other names
- semaglutide monthly depot
02
Targets
Beyond the preview
Go deeper on CAM2056.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAM2056.